MA34897B1 - Formulations d'immunosupresseurs - Google Patents

Formulations d'immunosupresseurs

Info

Publication number
MA34897B1
MA34897B1 MA36170A MA36170A MA34897B1 MA 34897 B1 MA34897 B1 MA 34897B1 MA 36170 A MA36170 A MA 36170A MA 36170 A MA36170 A MA 36170A MA 34897 B1 MA34897 B1 MA 34897B1
Authority
MA
Morocco
Prior art keywords
api
immunosuppressors
formations
compound
solvate
Prior art date
Application number
MA36170A
Other languages
English (en)
Inventor
Philippe Bouillot
Emeric Reynaud
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34897(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34897B1 publication Critical patent/MA34897B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique à phase solide comprenant un ou plusieurs excipients pharmaceutiquement acceptables et un ingrédient pharmaceutiquement actif (« API ») qui est un composé de formule A1 ou A2, ou un sel, solvate ou hydrate pharmacologiquement acceptable de celui-ci, dans lequel l'API n'est pas exposé à un composé basique.
MA36170A 2011-01-07 2012-01-05 Formulations d'immunosupresseurs MA34897B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150431 2011-01-07
PCT/EP2012/050151 WO2012093161A1 (fr) 2011-01-07 2012-01-05 Formulations d'immunosuppresseurs

Publications (1)

Publication Number Publication Date
MA34897B1 true MA34897B1 (fr) 2014-02-01

Family

ID=44022942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36170A MA34897B1 (fr) 2011-01-07 2012-01-05 Formulations d'immunosupresseurs

Country Status (36)

Country Link
US (4) US20130273161A1 (fr)
EP (2) EP3590507A1 (fr)
JP (2) JP6111202B2 (fr)
KR (2) KR102166885B1 (fr)
CN (1) CN103458877B (fr)
AR (2) AR084801A1 (fr)
AU (1) AU2012204835B2 (fr)
BR (1) BR112013017302B1 (fr)
CA (1) CA2823616C (fr)
CL (1) CL2013001979A1 (fr)
CO (1) CO6761402A2 (fr)
CY (1) CY1122182T1 (fr)
DK (1) DK2661261T3 (fr)
EA (1) EA026144B9 (fr)
EC (1) ECSP13012812A (fr)
ES (1) ES2751920T3 (fr)
GT (1) GT201300178A (fr)
HR (1) HRP20191842T1 (fr)
HU (1) HUE045612T2 (fr)
IL (1) IL227094B (fr)
JO (1) JO3619B1 (fr)
LT (1) LT2661261T (fr)
MA (1) MA34897B1 (fr)
MX (2) MX357304B (fr)
MY (1) MY161162A (fr)
PE (1) PE20140216A1 (fr)
PH (1) PH12013501442B1 (fr)
PL (1) PL2661261T3 (fr)
PT (1) PT2661261T (fr)
SG (1) SG191286A1 (fr)
SI (1) SI2661261T1 (fr)
TN (1) TN2013000257A1 (fr)
TW (2) TWI610672B (fr)
UA (1) UA114283C2 (fr)
WO (1) WO2012093161A1 (fr)
ZA (1) ZA201304465B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
KR102466348B1 (ko) * 2014-04-10 2022-11-10 노파르티스 아게 면역억제제 제제
CN106456552A (zh) * 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
WO2016135644A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
SMT202300074T1 (it) * 2015-07-03 2023-05-12 Astellas Pharma Inc Composizione farmaceutica stabile per somministrazione orale
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
ES3024636T3 (en) 2017-09-27 2025-06-04 Novartis Ag Parenteral formulation comprising siponimod
AU2018343239A1 (en) 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
WO2019064212A1 (fr) 2017-09-29 2019-04-04 Novartis Ag Schéma posologique de siponimod
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021214717A1 (fr) 2020-04-23 2021-10-28 Novartis Ag Schéma posologique pour l'utilisation de siponimod pour le traitement du syndrome de détresse respiratoire aiguë
CN119031939A (zh) * 2022-03-09 2024-11-26 埃斯普投资有限公司 共处理赋形剂组合物
US20260207513A1 (en) 2022-12-12 2026-07-23 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3872113A (en) 1972-05-30 1975-03-18 Endo Lab Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
EP0771339B1 (fr) 1994-07-12 2003-10-15 BPSI Holdings, Inc. Composition d'enrobage seche constituant une pellicule de protection contre l'humidite, procede d'enrobage de substrats l'utilisant et tablettes pharmaceutiques ainsi enrobees
WO1997024112A1 (fr) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. Preparation a usage externe
MY121470A (en) 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
WO2002018395A1 (fr) 2000-08-31 2002-03-07 Merck & Co., Inc. Derives de phosphates utilises en tant qu'agents immuno-regulateurs
AR041786A1 (es) 2002-03-15 2005-06-01 Novartis Ag Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
JP5227492B2 (ja) 2002-05-16 2013-07-03 ノバルティス アーゲー 癌におけるｅｄｇレセプター結合剤の使用
WO2004041229A1 (fr) * 2002-11-07 2004-05-21 Nippon Zettoc Co.,Ltd. Base pour composition orale et composition orale
CA2707750A1 (fr) 2003-04-08 2004-10-21 Novartis Ag Compositions pharmaceutiques solides contenant un antagoniste des recepteurs de la s1p et un alcool de sucre
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN102174042B (zh) 2003-05-19 2013-09-18 Irm有限责任公司 免疫抑制剂化合物和组合物
EP1628967B1 (fr) 2003-05-19 2014-04-09 Irm Llc Composés immunosuppresseurs et compositions
WO2005025553A2 (fr) 2003-09-12 2005-03-24 Neuronova Ab Traitement de maladies ou de lesions du systeme nerveux avec le fty720
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
WO2005105146A1 (fr) 2004-05-03 2005-11-10 Novartis Ag Combinaisons comprenant un agoniste du recepteur s1p et un inhibiteur de la kinase jak3
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2384749A1 (fr) 2004-11-29 2011-11-09 Novartis AG Posologie d'un agoniste du récepteur S1P
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
RU2296999C2 (ru) 2005-03-09 2007-04-10 Алексей Арнольдович Корженевский Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008072056A1 (fr) 2006-12-14 2008-06-19 Pfizer Limited Utilisation d'inhibiteurs de mtp pour traiter l'obésité au moyen de faibles doses et de doses augmentées
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
EP2142184B1 (fr) 2007-05-04 2018-10-24 Novartis AG Utilisation d'un modulateur des récepteurs s1p
WO2009048993A2 (fr) * 2007-10-12 2009-04-16 Novartis Ag Compositions comprenant des modulateurs du récepteur de sphingosine 1-phosphate (s1p)
CA2716448A1 (fr) 2008-03-17 2009-09-24 Patrick Brossard Regime de dosage pour un agoniste selectif du recepteur s1p<sb>1</sb>
WO2009155475A1 (fr) 2008-06-20 2009-12-23 Novartis Ag Compositions pédiatriques pour le traitement de la sclérose en plaques
RU2521286C2 (ru) 2008-07-23 2014-06-27 Новартис Аг Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
CA2733508A1 (fr) 2008-08-18 2010-02-25 David Leppert Composes destines au traitement de neuropathies peripheriques
AU2009327405A1 (en) * 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
RU2011129229A (ru) * 2008-12-18 2013-01-27 Новартис Аг Новые соли
HRP20131106T1 (hr) * 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
US20110247617A1 (en) 2008-12-19 2011-10-13 Thomas Nilsson Mouthpiece for an inhaler
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3831371A1 (fr) 2009-09-29 2021-06-09 Novartis AG Posologie d'un agoniste du récepteur s1p
SG191286A1 (en) 2011-01-07 2013-07-31 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
WO2014161606A1 (fr) 2013-04-04 2014-10-09 Novartis Ag Identification de la réponse d'un patient à une administration d'un modulateur de récepteur de s1p
KR102466348B1 (ko) 2014-04-10 2022-11-10 노파르티스 아게 면역억제제 제제

Also Published As

Publication number Publication date
BR112013017302A2 (pt) 2016-10-25
CA2823616C (fr) 2019-01-29
CY1122182T1 (el) 2020-11-25
EP2661261A1 (fr) 2013-11-13
PH12013501442A1 (en) 2013-09-09
EA026144B1 (ru) 2017-03-31
TWI583380B (zh) 2017-05-21
LT2661261T (lt) 2019-10-25
KR101951966B1 (ko) 2019-02-25
CL2013001979A1 (es) 2013-11-22
EA026144B9 (ru) 2021-10-26
CN103458877B (zh) 2016-06-08
CO6761402A2 (es) 2013-09-30
AU2012204835B2 (en) 2015-07-09
DK2661261T3 (da) 2019-10-21
JO3619B1 (ar) 2020-08-27
SG191286A1 (en) 2013-07-31
JP6111202B2 (ja) 2017-04-05
GT201300178A (es) 2014-12-30
EP2661261B1 (fr) 2019-07-31
UA114283C2 (uk) 2017-05-25
TW201249438A (en) 2012-12-16
NZ612420A (en) 2015-05-29
AR084801A1 (es) 2013-06-26
US20200199069A1 (en) 2020-06-25
US12071402B2 (en) 2024-08-27
PE20140216A1 (es) 2014-03-01
PH12013501442B1 (en) 2018-04-20
TWI610672B (zh) 2018-01-11
ECSP13012812A (es) 2013-09-30
KR20190025727A (ko) 2019-03-11
CA2823616A1 (fr) 2012-07-12
JP2017141248A (ja) 2017-08-17
BR112013017302B1 (pt) 2021-12-07
TW201609092A (zh) 2016-03-16
KR20140037815A (ko) 2014-03-27
AR124662A2 (es) 2023-04-19
WO2012093161A1 (fr) 2012-07-12
JP2014501770A (ja) 2014-01-23
JP6324569B2 (ja) 2018-05-16
PT2661261T (pt) 2019-10-25
EA201391018A1 (ru) 2013-11-29
MY161162A (en) 2017-04-14
SI2661261T1 (sl) 2019-11-29
US20250084034A1 (en) 2025-03-13
MX2013007909A (es) 2013-08-29
ES2751920T3 (es) 2020-04-02
US20130273161A1 (en) 2013-10-17
HUE045612T2 (hu) 2020-01-28
EP3590507A1 (fr) 2020-01-08
ZA201304465B (en) 2014-02-26
CN103458877A (zh) 2013-12-18
MX371290B (es) 2020-01-24
TN2013000257A1 (en) 2014-11-10
AU2012204835A1 (en) 2013-08-01
MX357304B (es) 2018-07-04
PL2661261T3 (pl) 2020-01-31
KR102166885B1 (ko) 2020-10-19
HRP20191842T1 (hr) 2019-12-27
IL227094B (en) 2019-03-31
US20220064110A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
TN2013000257A1 (en) Immunosuppressant formulations
TN2011000659A1 (fr) Formulation pharmaceutique
EP4483882A3 (fr) Nouveaux dérivés de méthylquinazolinone
MA33745B1 (fr) Piperidines substituees qui accroissent l&#39;activite de p53, et utilisation de ces composes
MX2010004232A (es) Compuesto de indolina de pirimidilo.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l&#39;amélioration ou la prévention d&#39;une maladie virale
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
SE0400284D0 (sv) Novel compounds
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu&#39;inhibiteurs de prmt5
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
EA201000050A1 (ru) Замещенные бициклолактамные соединения
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
MA38295A1 (fr) Dérivé d&#39;azole et de benzène
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MA39983B1 (fr) Dérivés de carboxamide
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
EA201692298A1 (ru) Производные карбоксамидов
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
SE0303480D0 (sv) Benzofuranes